Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.61 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in hepatocytes | 0.75 |
| chemistry Open Targets | compounds already reach it: rivastigmine, tacrine, propanidid +1 | 1.00 |
| trials ClinicalTrials.gov | 12 Parkinson's trials, 1 stopped | 0.93 |
| literature PubMed | 71 Parkinson's papers of 3,915 | 0.44 |
| pathways Reactome | 4 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 11453
Earlier readings: 2026-10-26 0.54; 2026-10-25 0.54; 2026-10-24 0.54; 2026-10-23 0.54.
Sealed predictions
- BCHE in oligodendrocytes, braak-0.31 (p 0.414) → +0.11 (p 0.784)receipt 0552
- BCHE in dopamine neurons, braak+0.41 (p 0.272) → +0.10 (p 0.803)receipt 0553
- BCHE in oligodendrocytes, resilience+0.07 (p 0.788) → +0.16 (p 0.580)receipt 0076
- BCHE in oligodendrocytes, braak-0.09 (p 0.583) → -0.13 (p 0.428)receipt 0075
Swarm cases
receipt 0553: BCHE in dopamine neurons, braak
- power
- full sample +0.29 (p 0.243, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.34 (p 0.164, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.32 (p 0.191, n 18). could be the mix.
- skeptic
- leave-one-out range +0.20 to +0.49, sign flips 0; without severely affected donors +0.29 (p 0.243, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BCHE in dopamine neurons.
case closed: nothing better to follow up.
receipt 0552: BCHE in oligodendrocytes, braak
- power
- full sample -0.12 (p 0.640, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.12 (p 0.640, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.13 (p 0.615, n 18). could be the mix.
- skeptic
- leave-one-out range -0.23 to +0.01, sign flips 1; without severely affected donors -0.12 (p 0.640, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BCHE in oligodendrocytes.
case closed: nothing better to follow up.
receipt 0076: BCHE in oligodendrocytes, resilience
- power
- full sample +0.13 (p 0.514, n 55), 95% CI -0.14 to +0.38. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: +0.14 (p 0.487, n 55). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis -0.52 (p 0.0075); controlling for it: +0.14 (p 0.487, n 55). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.24, sign flips 0; without severely affected donors +0.10 (p 0.634, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for BCHE in oligodendrocytes.
case closed: nothing better to follow up.
receipt 0075: BCHE in oligodendrocytes, braak
- power
- full sample -0.08 (p 0.443, n 84), 95% CI -0.29 to +0.13. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: -0.00 (p 0.992, n 84). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.09 (p 0.422); controlling for it: -0.00 (p 0.982, n 84). could be the mix.
- skeptic
- leave-one-out range -0.12 to -0.06, sign flips 0; without severely affected donors -0.03 (p 0.812, n 75). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BCHE in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts